182 related articles for article (PubMed ID: 36831263)
1. In Silico Identification and Functional Characterization of Genetic Variations across DLBCL Cell Lines.
Dharanipragada P; Parekh N
Cells; 2023 Feb; 12(4):. PubMed ID: 36831263
[TBL] [Abstract][Full Text] [Related]
2. PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma.
Pfeifer M; Grau M; Lenze D; Wenzel SS; Wolf A; Wollert-Wulf B; Dietze K; Nogai H; Storek B; Madle H; Dörken B; Janz M; Dirnhofer S; Lenz P; Hummel M; Tzankov A; Lenz G
Proc Natl Acad Sci U S A; 2013 Jul; 110(30):12420-5. PubMed ID: 23840064
[TBL] [Abstract][Full Text] [Related]
3. Characterization of genomic imbalances in diffuse large B-cell lymphoma by detailed SNP-chip analysis.
Scholtysik R; Kreuz M; Hummel M; Rosolowski M; Szczepanowski M; Klapper W; Loeffler M; Trümper L; Siebert R; Küppers R;
Int J Cancer; 2015 Mar; 136(5):1033-42. PubMed ID: 25042405
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide characterization of copy number variations in diffuse large B-cell lymphoma with implications in targeted therapy.
Dharanipragada P; Parekh N
Precis Clin Med; 2019 Dec; 2(4):246-258. PubMed ID: 35693879
[TBL] [Abstract][Full Text] [Related]
5. Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing.
Morin RD; Mungall K; Pleasance E; Mungall AJ; Goya R; Huff RD; Scott DW; Ding J; Roth A; Chiu R; Corbett RD; Chan FC; Mendez-Lago M; Trinh DL; Bolger-Munro M; Taylor G; Hadj Khodabakhshi A; Ben-Neriah S; Pon J; Meissner B; Woolcock B; Farnoud N; Rogic S; Lim EL; Johnson NA; Shah S; Jones S; Steidl C; Holt R; Birol I; Moore R; Connors JM; Gascoyne RD; Marra MA
Blood; 2013 Aug; 122(7):1256-65. PubMed ID: 23699601
[TBL] [Abstract][Full Text] [Related]
6. Diffuse large B-cell lymphoma.
Li S; Young KH; Medeiros LJ
Pathology; 2018 Jan; 50(1):74-87. PubMed ID: 29167021
[TBL] [Abstract][Full Text] [Related]
7. Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets.
Karube K; Enjuanes A; Dlouhy I; Jares P; Martin-Garcia D; Nadeu F; Ordóñez GR; Rovira J; Clot G; Royo C; Navarro A; Gonzalez-Farre B; Vaghefi A; Castellano G; Rubio-Perez C; Tamborero D; Briones J; Salar A; Sancho JM; Mercadal S; Gonzalez-Barca E; Escoda L; Miyoshi H; Ohshima K; Miyawaki K; Kato K; Akashi K; Mozos A; Colomo L; Alcoceba M; Valera A; Carrió A; Costa D; Lopez-Bigas N; Schmitz R; Staudt LM; Salaverria I; López-Guillermo A; Campo E
Leukemia; 2018 Mar; 32(3):675-684. PubMed ID: 28804123
[TBL] [Abstract][Full Text] [Related]
8. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.
Lenz G; Wright GW; Emre NC; Kohlhammer H; Dave SS; Davis RE; Carty S; Lam LT; Shaffer AL; Xiao W; Powell J; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Campo E; Jaffe ES; Delabie J; Smeland EB; Rimsza LM; Fisher RI; Weisenburger DD; Chan WC; Staudt LM
Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13520-5. PubMed ID: 18765795
[TBL] [Abstract][Full Text] [Related]
9. Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.
Dubois S; Viailly PJ; Bohers E; Bertrand P; Ruminy P; Marchand V; Maingonnat C; Mareschal S; Picquenot JM; Penther D; Jais JP; Tesson B; Peyrouze P; Figeac M; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Fabiani B; Delarue R; Peyrade F; André M; Ketterer N; Leroy K; Salles G; Molina TJ; Tilly H; Jardin F
Clin Cancer Res; 2017 May; 23(9):2232-2244. PubMed ID: 27923841
[No Abstract] [Full Text] [Related]
10. Frequent copy number variations of PI3K/AKT pathway and aberrant protein expressions of PI3K subunits are associated with inferior survival in diffuse large B cell lymphoma.
Cui W; Cai Y; Wang W; Liu Z; Wei P; Bi R; Chen W; Sun M; Zhou X
J Transl Med; 2014 Jan; 12():10. PubMed ID: 24418330
[TBL] [Abstract][Full Text] [Related]
11. B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice.
Knittel G; Liedgens P; Korovkina D; Seeger JM; Al-Baldawi Y; Al-Maarri M; Fritz C; Vlantis K; Bezhanova S; Scheel AH; Wolz OO; Reimann M; Möller P; López C; Schlesner M; Lohneis P; Weber AN; Trümper L; ; Staudt LM; Ortmann M; Pasparakis M; Siebert R; Schmitt CA; Klatt AR; Wunderlich FT; Schäfer SC; Persigehl T; Montesinos-Rongen M; Odenthal M; Büttner R; Frenzel LP; Kashkar H; Reinhardt HC
Blood; 2016 Jun; 127(22):2732-41. PubMed ID: 27048211
[TBL] [Abstract][Full Text] [Related]
12. Tonic B-cell receptor signaling in diffuse large B-cell lymphoma.
Havranek O; Xu J; Köhrer S; Wang Z; Becker L; Comer JM; Henderson J; Ma W; Man Chun Ma J; Westin JR; Ghosh D; Shinners N; Sun L; Yi AF; Karri AR; Burger JA; Zal T; Davis RE
Blood; 2017 Aug; 130(8):995-1006. PubMed ID: 28646116
[TBL] [Abstract][Full Text] [Related]
13. ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma.
Sartori G; Napoli S; Cascione L; Chung EYL; Priebe V; Arribas AJ; Mensah AA; Dall'Angelo M; Falzarano C; Barnabei L; Forcato M; Rinaldi A; Bicciato S; Thome M; Bertoni F
J Exp Clin Cancer Res; 2021 Nov; 40(1):357. PubMed ID: 34763718
[TBL] [Abstract][Full Text] [Related]
14. PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma.
Chen J; Ge X; Zhang W; Ding P; Du Y; Wang Q; Li L; Fang L; Sun Y; Zhang P; Zhou Y; Zhang L; Lv X; Li L; Zhang X; Zhang Q; Xue K; Gu H; Lei Q; Wong J; Hu W
Theranostics; 2020; 10(7):3151-3163. PubMed ID: 32194860
[TBL] [Abstract][Full Text] [Related]
15. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.
Chapuy B; Stewart C; Dunford AJ; Kim J; Kamburov A; Redd RA; Lawrence MS; Roemer MGM; Li AJ; Ziepert M; Staiger AM; Wala JA; Ducar MD; Leshchiner I; Rheinbay E; Taylor-Weiner A; Coughlin CA; Hess JM; Pedamallu CS; Livitz D; Rosebrock D; Rosenberg M; Tracy AA; Horn H; van Hummelen P; Feldman AL; Link BK; Novak AJ; Cerhan JR; Habermann TM; Siebert R; Rosenwald A; Thorner AR; Meyerson ML; Golub TR; Beroukhim R; Wulf GG; Ott G; Rodig SJ; Monti S; Neuberg DS; Loeffler M; Pfreundschuh M; Trümper L; Getz G; Shipp MA
Nat Med; 2018 May; 24(5):679-690. PubMed ID: 29713087
[TBL] [Abstract][Full Text] [Related]
16. Oncogenically active MYD88 mutations in human lymphoma.
Ngo VN; Young RM; Schmitz R; Jhavar S; Xiao W; Lim KH; Kohlhammer H; Xu W; Yang Y; Zhao H; Shaffer AL; Romesser P; Wright G; Powell J; Rosenwald A; Muller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Staudt LM
Nature; 2011 Feb; 470(7332):115-9. PubMed ID: 21179087
[TBL] [Abstract][Full Text] [Related]
17. PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells.
Zhu F; Guo H; Bates PD; Zhang S; Zhang H; Nomie KJ; Li Y; Lu L; Seibold KR; Wang F; Rumball I; Cameron H; Hoang NM; Yang DT; Xu W; Zhang L; Wang M; Capitini CM; Rui L
Leukemia; 2019 Dec; 33(12):2898-2911. PubMed ID: 31123343
[TBL] [Abstract][Full Text] [Related]
18. Prediction and characterization of diffuse large B-cell lymphoma cell-of-origin subtypes using targeted sequencing.
Trabucco SE; Sokol ES; Maund SL; Moore JA; Frampton GM; Albacker LA; Oestergaard MZ; Venstrom J; Sehn LH; Bolen CR
Future Oncol; 2021 Nov; 17(31):4171-4183. PubMed ID: 34313135
[TBL] [Abstract][Full Text] [Related]
19. Proteasomal cysteine deubiquitinase inhibitor b-AP15 suppresses migration and induces apoptosis in diffuse large B cell lymphoma.
Jiang L; Sun Y; Wang J; He Q; Chen X; Lan X; Chen J; Dou QP; Shi X; Liu J
J Exp Clin Cancer Res; 2019 Nov; 38(1):453. PubMed ID: 31694672
[TBL] [Abstract][Full Text] [Related]
20. The significance of FOXP1 in diffuse large B-cell lymphoma.
Gascoyne DM; Banham AH
Leuk Lymphoma; 2017 May; 58(5):1037-1051. PubMed ID: 27678023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
